Journal ArticleDOI
Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor.
Daniela Katz,Amiel Segal,Yossef Alberton,Oded Jurim,Petachia Reissman,Raphael Catane,Nathan I. Cherny +6 more
Reads0
Chats0
TLDR
It is concluded that in the management of unresectable gastrointestinal stromal tumors, neoadjuvant administration of imatinib may facilitate sufficient tumor regression to facilitate subsequent tumor resection with curative intent.Abstract:
We have evaluated the feasibility of the use of neoadjuvant imatinib mesylate in the management of unresectable localized gastrointestinal stromal tumors. In a pilot experience, two patients with unresectable gastrointestinal tumors were treated with neoadjuvant imatinib. Their treatment course and surgical outcomes are described. In both cases, the patient attained sufficient tumor regression to enable complete resection of tumor. We conclude that in the management of unresectable gastrointestinal stromal tumors, neoadjuvant administration of imatinib may facilitate sufficient tumor regression to facilitate subsequent tumor resection with curative intent.read more
Citations
More filters
Journal ArticleDOI
Surgical Resection of Gastrointestinal Stromal Tumors After Treatment with Imatinib
Robert H.I. Andtbacka,Chaan S. Ng,Courtney L. Scaife,Janice N. Cormier,Kelly K. Hunt,Peter W.T. Pisters,Raphael E. Pollock,Robert S. Benjamin,Michael A. Burgess,Lei L. Chen,Jonathan C. Trent,Shreyaskumar Patel,Kevin Raymond,Barry W. Feig +13 more
TL;DR: Preoperative imatinib can decrease tumor volume and is associated with complete surgical resection in locally advanced primary GISTs and early surgical intervention should be considered for imatinIB-responsive recurrent or metastatic GIST, since complete resection is rarely achieved once tumor progression occurs.
Journal ArticleDOI
Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience
Piotr Rutkowski,Alessandro Gronchi,Peter Hohenberger,Sylvie Bonvalot,Patrick Schöffski,Sebastian Bauer,Elena Fumagalli,Paweł Nyckowski,Buu Phuc Nguyen,J.M. Kerst,Marco Fiore,Elżbieta Bylina,Mathias Hoiczyk,Annemieke Cats,Paolo G. Casali,Axel Le Cesne,Jürgen Treckmann,Eberhard Stoeckle,Johannes H. W. de Wilt,Stefan Sleijfer,R. Tielen,Winette T. A. van der Graaf,Cornelis Verhoef,Frits van Coevorden +23 more
TL;DR: The authors' analysis comprising the largest group of GIST patients treated with neoadjuvant imatinib in routine practice indicates excellent long-term results of combined therapy in locally advanced GISTs.
Journal ArticleDOI
Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).
M. Fiore,Elena Palassini,Elena Fumagalli,S. Pilotti,Elena Tamborini,Silvia Stacchiotti,Elisabetta Pennacchioli,Paolo G. Casali,Alessandro Gronchi +8 more
TL;DR: In unresectable or locally advanced GISTs, preoperative IM is a useful tool both to improve resectability and reduce surgical morbidity and it should be therefore always be considered before embarking on a major surgical procedure.
Journal ArticleDOI
Impact of Surgery on Advanced Gastrointestinal Stromal Tumors (GIST) in the Imatinib Era
S. Bonvalot,H. Eldweny,C. Le Pechoux,Daniel Vanel,P. Terrier,Andrea Cavalcanti,Caroline Robert,Nathalie Lassau,A. Le Cesne +8 more
TL;DR: Primary tumors that become amenable to surgery with prior imatinib therapy, evolving necrosis and localized progression (to avoid life-threatening complications) could benefit from this secondary surgery.
Journal ArticleDOI
Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment.
Martin E. Blackstein,Jean-Yves Blay,Christopher L. Corless,David K. Driman,Robert H. Riddell,Denis Soulières,Carol J. Swallow,Shailendra Verma +7 more
TL;DR: Imatinib 400 mg/day with or without surgery is the recommended first-line treatment for recurrent or metastatic GIST; a higher dose may be considered in patients who progress, develop secondary resistance or present with specific genotypic characteristics.
References
More filters
Journal ArticleDOI
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Brian J. Druker,Moshe Talpaz,Debra Resta,Bin Peng,Elisabeth Buchdunger,John Ford,Nicholas B. Lydon,Hagop M. Kantarjian,Renaud Capdeville,Sayuri Ohno-Jones,Charles L. Sawyers +10 more
TL;DR: STI571 is well tolerated and has significant antileukemic activity in patients with CML in whom treatment with interferon alfa had failed and demonstrates the potential for the development of anticancer drugs based on the specific molecular abnormality present in a human cancer.
Journal ArticleDOI
Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.
Seiichi Hirota,Koji Isozaki,Yasuhiro Moriyama,Koji Hashimoto,Toshirou Nishida,Shingo Ishiguro,Kiyoshi Kawano,Masato Hanada,Akihiko Kurata,Masashi Takeda,Ghulam Muhammad Tunio,Yuji Matsuzawa,Yuzuru Kanakura,Yasuhisa Shinomura,Yukihiko Kitamura +14 more
TL;DR: Sequencing of c-kit complementary DNA from five GISTs revealed mutations in the region between the transmembrane and tyrosine kinase domains, suggesting that the mutations contribute to tumor development.
Journal ArticleDOI
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
George D. Demetri,Margaret von Mehren,Charles D. Blanke,Annick D. Van den Abbeele,Burton L. Eisenberg,Peter J. Roberts,Michael Heinrich,David A. Tuveson,Samuel Singer,Milos J. Janicek,Jonathan A. Fletcher,Stuart G. Silverman,Sandra Silberman,Renaud Capdeville,Beate Kiese,Bin Peng,Sasa Dimitrijevic,Brian J. Druker,Christopher L. Corless,Christopher D.M. Fletcher,Heikki Joensuu +20 more
TL;DR: Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor, indicating that inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinalStromal tumors, which resist conventional chemotherapy.
Journal ArticleDOI
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
Brian J. Druker,Charles L. Sawyers,Hagop M. Kantarjian,Debra Resta,Sofia Fernandes Reese,John Ford,Renaud Capdeville,Moshe Talpaz +7 more
TL;DR: The BCR-ABL tyrosine kinase inhibitor STI571 is well tolerated and has substantial activity in the blast crises of CML and in Ph-positive ALL.
Journal ArticleDOI
Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor
Heikki Joensuu,Peter J. Roberts,Maarit Sarlomo-Rikala,Leif C. Andersson,Pekka Tervahartiala,David A. Tuveson,David A. Tuveson,Sandra Silberman,Renaud Capdeville,Sasa Dimitrijevic,Brian J. Druker,George D. Demetri +11 more
TL;DR: Gastrointestinal stromal tumors are a group of mesenchymal neoplasms that arise from precursors of the connective-tissue cells of the gastrointestinal tract that occur predominantly in middle-aged and older persons.
Related Papers (5)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
George D. Demetri,Margaret von Mehren,Charles D. Blanke,Annick D. Van den Abbeele,Burton L. Eisenberg,Peter J. Roberts,Michael Heinrich,David A. Tuveson,Samuel Singer,Milos J. Janicek,Jonathan A. Fletcher,Stuart G. Silverman,Sandra Silberman,Renaud Capdeville,Beate Kiese,Bin Peng,Sasa Dimitrijevic,Brian J. Druker,Christopher L. Corless,Christopher D.M. Fletcher,Heikki Joensuu +20 more